Skip to main content
Contact Us
Subscribe
E-Edition
68°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.100
+0.030 (+2.80%)
Streaming Delayed Price
Updated: 1:35 PM EST, Dec 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
November 26, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
November 15, 2024
Via
ACCESSWIRE
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
October 30, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
3 Health Care Stocks Moving In Thursday's Intraday Session
October 24, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
October 25, 2024
Via
Benzinga
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
October 23, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
October 16, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
September 10, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
September 05, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
August 27, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
OKYO Pharma CEO Interview to Air on Bloomberg TV
August 23, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Chairman Acquires Shares
August 23, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
August 23, 2024
Via
ACCESSWIRE
OKYO Pharma Announces Chairman Acquires Shares
August 21, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 15, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
August 06, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
July 11, 2024
Via
Benzinga
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
July 10, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Participation in May 2024 Investor Conferences
May 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
April 30, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
April 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
April 02, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
March 25, 2024
Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results.
Via
Benzinga
Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study
March 22, 2024
Latest findings from OKYO Pharma's Phase 2 trial on OK-101 for dry eye disease. Significant reductions in ocular pain, improved Tear Film Break-Up Time, and symptomatic relief were observed....
Via
Benzinga
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
March 22, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
March 20, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.